Exhibit 99.1
     
(ALPHARMA LOGO)   News Release
February 26, 2008
Alpharma Reports Double-Digit Full Year and Fourth Quarter 2007 Revenue Growth
Bridgewater, NJ...February 26, 2008...Alpharma Inc. (NYSE:ALO), a global specialty pharmaceutical company, today announced financial results for the full year and fourth quarter ended December 31, 2007.
Full year 2007 revenues totaled $722.4 million, an increase of 10% over the $653.8 million reported for 2006. Reported 2007 results, which amounted to a diluted loss per share of $0.32, include an upfront payment of $60 million made to IDEA AG (“IDEA”) in October 2007 in connection with the Company’s license of the exclusive United States rights to ketoprofen in Transfersome® gel, a topical NSAID (non-steroidal anti-inflammatory drug) in clinical development. Excluding this $60 million upfront payment, full year 2007 EPS was $1.06*. The Company’s full year performance (excluding the $60 million upfront payment) reflects:
    EPS of $1.06*, exceeding the Company’s most recent outlook of $0.90 to $1.00;
 
    Revenue gains meeting or exceeding the Company’s outlook in all three business segments; and
 
    Earnings before interest, taxes, depreciation and amortization (“EBITDA”) of $114 million* and free cash flow of $45 million*
On February 6, 2008, the Company announced that it has entered into an agreement to sell its Active Pharmaceutical Ingredients business to certain investment funds managed by 3i, a global private equity and venture capital company, for $395 million in cash. The final purchase price is subject to adjustment based on the closing net cash balance and working capital of the business and the transaction is expected to close in the second quarter of 2008, pending regulatory approvals and other customary closing conditions. Upon closing, the Company will record a gain on the transaction.
 
*   A reconciliation of reported to adjusted results for the three months and years ended December 31, 2007 and 2006, is attached to this release.
Alpharma Inc.
440 Route 22 East
Bridgewater, NJ 08807


The following information was filed by Alpharma Inc on Tuesday, February 26, 2008 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alpharma Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alpharma Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account